vTv Therapeutics Inc. - (VTVT): Price and Financial Metrics


vTv Therapeutics Inc. - (VTVT): $1.83

0.06 (+3.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VTVT POWR Grades


  • Sentiment is the dimension where VTVT ranks best; there it ranks ahead of 90.65% of US stocks.
  • The strongest trend for VTVT is in Value, which has been heading up over the past 48 weeks.
  • VTVT's current lowest rank is in the Momentum metric (where it is better than 5.12% of US stocks).

VTVT Stock Summary

  • VTVT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 5.54% of US stocks.
  • With a year-over-year growth in debt of -86.11%, vTv Therapeutics Inc's debt growth rate surpasses just 3.04% of about US stocks.
  • Revenue growth over the past 12 months for vTv Therapeutics Inc comes in at 32,082.61%, a number that bests 100% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to vTv Therapeutics Inc are RGLS, AUPH, ATHX, SAGE, and IPWR.
  • Visit VTVT's SEC page to see the company's official filings. To visit the company's web site, go to www.vtvtherapeutics.com.

VTVT Valuation Summary

  • In comparison to the median Healthcare stock, VTVT's EV/EBIT ratio is 200.68% lower, now standing at -29.5.
  • Over the past 74 months, VTVT's EV/EBIT ratio has gone down 16.9.
  • Over the past 74 months, VTVT's price/sales ratio has gone down 218.2.

Below are key valuation metrics over time for VTVT.

Stock Date P/S P/B P/E EV/EBIT
VTVT 2021-08-31 21.0 -3.3 -29.6 -29.5
VTVT 2021-08-30 21.3 -3.3 -29.9 -29.8
VTVT 2021-08-27 20.8 -3.2 -29.3 -29.2
VTVT 2021-08-26 20.5 -3.2 -28.8 -28.6
VTVT 2021-08-25 20.8 -3.2 -29.3 -29.2
VTVT 2021-08-24 19.9 -3.1 -28.0 -27.8

VTVT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VTVT has a Quality Grade of D, ranking ahead of 10.38% of graded US stocks.
  • VTVT's asset turnover comes in at 0.491 -- ranking 90th of 677 Pharmaceutical Products stocks.
  • AMPH, ADXS, and ZYNE are the stocks whose asset turnover ratios are most correlated with VTVT.

The table below shows VTVT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.491 1 -1.393
2021-03-31 0.601 1 -5.046
2020-12-31 0.644 1 196.403
2020-09-30 0.003 1 20.944
2020-06-30 0.003 1 38.942
2020-03-31 0.212 1 -34.603

VTVT Price Target

For more insight on analysts targets of VTVT, see our VTVT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.75 Average Broker Recommendation 1.5 (Moderate Buy)

VTVT Stock Price Chart Interactive Chart >

Price chart for VTVT

VTVT Price/Volume Stats

Current price $1.83 52-week high $4.75
Prev. close $1.77 52-week low $1.44
Day low $1.77 Volume 50,274,600
Day high $2.17 Avg. volume 3,621,767
50-day MA $1.86 Dividend yield N/A
200-day MA $2.30 Market Cap 152.42M

vTv Therapeutics Inc. - (VTVT) Company Bio


vTv Therapeutics Inc., a biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company was founded in 2015 and is based in High Point, North Carolina.


VTVT Latest News Stream


Event/Time News Detail
Loading, please wait...

VTVT Latest Social Stream


Loading social stream, please wait...

View Full VTVT Social Stream

Latest VTVT News From Around the Web

Below are the latest news stories about vTv Therapeutics Inc that investors may wish to consider to help them evaluate VTVT as an investment opportunity.

vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects Results build on data from previous multiple ascending dose study and support advancement of HPP737 into Phase 2 in moderate to severe psoriasis. Successful pre-IND meeting with U.S. Food and Drug Administration Division of Dermatology and Dentistry supports planned IND submission for a Phase 2 study in moderate to severe psoriasis. HIGH POINT, N.C., Sept. 23, 2021 (GLOBE NEWSWIRE) --

Yahoo | September 23, 2021

Multiple insiders bought vTv Therapeutics Inc. (NASDAQ:VTVT) stock earlier this year, a positive sign for shareholders

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Yahoo | September 13, 2021

7 Penny Stocks Waiting on the FDA for Rocket Fuel

News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks.

Thomas Niel on InvestorPlace | September 9, 2021

Oral Insulin Market Competitive Research And Precise Outlook 2021 To 2025 -Novo Nordisk A/S, Oramed Pharmaceuticals Inc., vTv Therapeutics

The Global Oral Insulin Market Report 2021 provides an in-depth analysis of key players'' strategies, market growth, product demand, growth factors, technological innovations, regional outlook and global dynamics which includes drivers, challenges, and opportunities dominant in the industry. This Market

OpenPR | September 6, 2021

Down 16.1% in 4 Weeks, Here's Why vTv Therapeutics (VTVT) Looks Ripe for a Turnaround

vTv Therapeutics (VTVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | August 17, 2021

Read More 'VTVT' Stories Here

VTVT Price Returns

1-mo 0.55%
3-mo -20.09%
6-mo -28.52%
1-year 4.57%
3-year 135.52%
5-year -74.69%
YTD -1.61%
2020 9.41%
2019 -35.85%
2018 -55.91%
2017 24.43%
2016 -29.07%

Continue Researching VTVT

Want to see what other sources are saying about vTv Therapeutics Inc's financials and stock price? Try the links below:

vTv Therapeutics Inc (VTVT) Stock Price | Nasdaq
vTv Therapeutics Inc (VTVT) Stock Quote, History and News - Yahoo Finance
vTv Therapeutics Inc (VTVT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.3291 seconds.